PE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bn

Private equity firms such as Warburg Pincus and CVC Capital Partners have evinced interest in Orbicular Pharma as the specialty pharma firm explores a stake sale in a deal that will likely value the company up to $1.5 billion.
Key takeaways
- Category: Orders & Deals.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.










